BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 36508458)

  • 21. Effect of annual mass administration of diethylcarbamazine and albendazole on bancroftian filariasis in five villages in south India.
    Ramaiah KD; Vanamail P; Yuvaraj J; Das PK
    Trans R Soc Trop Med Hyg; 2011 Aug; 105(8):431-7. PubMed ID: 21601901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphatic filariasis control in Tanga Region, Tanzania: status after eight rounds of mass drug administration.
    Simonsen PE; Derua YA; Magesa SM; Pedersen EM; Stensgaard AS; Malecela MN; Kisinza WN
    Parasit Vectors; 2014 Nov; 7():507. PubMed ID: 25387483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of treatment with single doses of diethylcarbamazine (DEC) and DEC plus albendazole (ABZ) for three consecutive years in lymphatic filariasis: a field study in India.
    Kshirsagar NA; Gogtay NJ; Garg BS; Deshmukh PR; Rajgor DD; Kadam VS; Thakur PA; Gupta A; Ingole NS; Lazdins-Helds JK
    Parasitol Res; 2017 Oct; 116(10):2683-2694. PubMed ID: 28785847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphatic filariasis control in Tanzania: infection, disease perceptions and drug uptake patterns in an endemic community after multiple rounds of mass drug administration.
    Derua YA; Kisinza WN; Simonsen PE
    Parasit Vectors; 2018 Jul; 11(1):429. PubMed ID: 30029675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia.
    Supali T; Djuardi Y; ; Sianipar LR; Suryaningtyas NH; Alfian R; Destani Y; Iskandar E; Astuty H; Sugianto N; Fischer PU
    Am J Trop Med Hyg; 2024 Jan; 110(1):111-116. PubMed ID: 38011734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Are Alternative Strategies Required to Accelerate the Global Elimination of Lymphatic Filariasis? Insights From Mathematical Models.
    Stolk WA; Prada JM; Smith ME; Kontoroupis P; de Vos AS; Touloupou P; Irvine MA; Brown P; Subramanian S; Kloek M; Michael E; Hollingsworth TD; de Vlas SJ
    Clin Infect Dis; 2018 Jun; 66(suppl_4):S260-S266. PubMed ID: 29860286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Value of Microfilariae-Based Stop-MDA Thresholds After Triple Drug Therapy With IDA Against Lymphatic Filariasis in Treatment-Naive Indian Settings.
    James A; Coffeng LE; Blok DJ; King JD; de Vlas SJ; Stolk WA
    Clin Infect Dis; 2024 Apr; 78(Supplement_2):S131-S137. PubMed ID: 38662696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ongoing transmission of lymphatic filariasis in Samoa 4.5 years after one round of triple-drug mass drug administration.
    Mayfield HJ; Sartorius B; Sheridan S; Howlett M; Martin BM; Thomsen R; Tofaeono-Pifeleti R; Viali S; Graves PM; Lau CL
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012236. PubMed ID: 38935622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress on elimination of lymphatic filariasis in Sierra Leone.
    Koroma JB; Sesay S; Conteh A; Paye J; Bah M; Sonnie M; Hodges MH; Zhang Y
    Parasit Vectors; 2018 Jun; 11(1):334. PubMed ID: 29866207
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elimination within reach: A cross-sectional study highlighting the factors that contribute to persistent lymphatic filariasis in eight communities in rural Ghana.
    Minetti C; Tettevi EJ; Mechan F; Prada JM; Idun B; Biritwum NK; Osei-Atweneboana MY; Reimer LJ
    PLoS Negl Trop Dis; 2019 Jan; 13(1):e0006994. PubMed ID: 30608931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.
    Ramaiah KD; Vanamail P; Pani SP; Yuvaraj J; Das PK
    Trop Med Int Health; 2002 Sep; 7(9):767-74. PubMed ID: 12225508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Annual versus Semiannual Mass Drug Administration with Ivermectin and Albendazole on Helminth Infections in Southeastern Liberia.
    Eneanya OA; Gankpala L; Goss CW; Bolay FK; Weil GJ; Fischer PU
    Am J Trop Med Hyg; 2021 Nov; 106(2):700-709. PubMed ID: 34814104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Step towards elimination of Wuchereria bancrofti in Southwest Tanzania 10 years after mass drug administration with Albendazole and Ivermectin.
    Mnkai J; Marandu TF; Mhidze J; Urio A; Maganga L; Haule A; Kavishe G; Ntapara E; Chiwerengo N; Clowes P; Horn S; Mosoba M; Lazarus W; Ngenya A; Kalinga A; Debrah A; Rieß F; Saathoff E; Geldmacher C; Hoerauf A; Hoelscher M; Chachage M; Kroidl I
    PLoS Negl Trop Dis; 2022 Jul; 16(7):e0010044. PubMed ID: 35857778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Achievements and challenges of lymphatic filariasis elimination in Sierra Leone.
    Bah YM; Paye J; Bah MS; Conteh A; Redwood-Sawyerr V; Sonnie M; Veinoglou A; Koroma JB; Hodges MH; Zhang Y
    PLoS Negl Trop Dis; 2020 Dec; 14(12):e0008877. PubMed ID: 33370270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular xenomonitoring as a post-MDA surveillance tool for global programme to eliminate lymphatic filariasis: Field validation in an evaluation unit in India.
    Subramanian S; Jambulingam P; Krishnamoorthy K; Sivagnaname N; Sadanandane C; Vasuki V; Palaniswamy C; Vijayakumar B; Srividya A; Raju HKK
    PLoS Negl Trop Dis; 2020 Jan; 14(1):e0007862. PubMed ID: 31978060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities.
    Biritwum NK; Frempong KK; Verver S; Odoom S; Alomatu B; Asiedu O; Kontoroupis P; Yeboah A; Hervie ET; Marfo B; Boakye DA; de Vlas SJ; Gyapong JO; Stolk WA
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007115. PubMed ID: 31398203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
    de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
    Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.